Table 2.
TAP study reported subgroup analyses at 24 months by treatment group and baseline characteristics*
| Characteristic Examined | Subgroup | PDT/Con | N | Number losing <15 letters (%)† | Difference % | p Value‡ | |
| 1. Trial | Study A | PDT | 204 | 104 | (51.0) | 11.7 | 0.39 |
| Con | 107 | 42 | (39.3) | ||||
| Study B | PDT | 198 | 109 | (55.1) | 19.1 | ||
| Con | 100 | 36 | (36.0) | ||||
| 2. Age | <75 | PDT | 194 | 115 | (59.3) | 17.9 | 0.53 |
| Con | 87 | 36 | (41.4) | ||||
| ⩾75 | PDT | 208 | 98 | (47.1) | 12.1 | ||
| Con | 120 | 42 | (35.0) | ||||
| 3. Gender | Men | PDT | 188 | 95 | (50.5) | 16.8 | 0.82 |
| Con | 77 | 26 | (33.8) | ||||
| Women | PDT | 214 | 118 | (55.1) | 15.1 | ||
| Con | 130 | 52 | (40.0) | ||||
| 4. Systemic hypertension | Definite§ | PDT | 170 | 90 | (52.9) | 20.5 | 0.33 |
| Con | 77 | 25 | (32.5) | ||||
| Others | PDT | 232 | 123 | (53.0) | 12.2 | ||
| Con | 130 | 53 | (40.8) | ||||
| 5. Smoking history | Never | PDT | 135 | 76 | (56.3) | 21.5 | 0.51 |
| Con | 89 | 31 | (34.8) | ||||
| Past | PDT | 205 | 104 | (50.7) | 11.4 | ||
| Con | 94 | 37 | (39.4) | ||||
| Current | PDT | 62 | 33 | (53.2) | 11.6 | ||
| Con | 24 | 10 | (41.7) | ||||
| 6. Initial letter score (visual acuity¶) in study eye | 73 to 54 | PDT | 203 | 89 | (43.8) | 9.2 | 0.16 |
| (20/40 to 20/80) | Con | 101 | 35 | (34.7) | |||
| 53 to 34 | PDT | 199 | 124 | (62.3) | 21.7 | ||
| (20/100 to 20/200) | Con | 106 | 43 | (40.6) | |||
| 7. Greatest linear dimension, diameter of MPS disc area circle | ⩽3 | PDT | 107 | 66 | (61.7) | 11.7 | 0.22 |
| Con | 46 | 23 | (50.0) | ||||
| >3 to ⩽6 | PDT | 152 | 84 | (55.6) | 23.7 | ||
| Con | 97 | 31 | (32.0) | ||||
| >6 to ⩽9 | PDT | 109 | 44 | (40.4) | 1.9 | ||
| Con | 52 | 20 | (38.5) | ||||
| >9 | PDT | 25 | 11 | (44.0) | 19.0 | ||
| Con | 8 | 2 | (25.0) | ||||
| 8. Lesion area composed of classic CNV, % | ⩾50 | PDT | 159 | 94 | (59.1) | 27.8 | 0.02 |
| Con | 83 | 26 | (31.3) | ||||
| >0 to <50 | PDT | 202 | 96 | (47.5) | 3.3 | ||
| Con | 104 | 46 | (44.2) | ||||
| 0 | PDT | 41 | 23 | (56.1) | 26.1 | ||
| Con | 20 | 6 | (30.0) | ||||
| 9. Evidence of occult CNV | Yes | PDT | 305 | 146 | (47.7) | 6.9 | <0.001 |
| Con | 157 | 64 | (40.8) | ||||
| No | PDT | 93 | 65 | (69.9) | 41.3 | ||
| Con | 49 | 14 | (28.6) | ||||
| 10. Evidence of prior laser photocoagulation | Yes | PDT | 60 | 28 | (46.7) | 3.2 | 0.29 |
| Con | 23 | 10 | (43.5) | ||||
| No | PDT | 340 | 183 | (53.8) | 16.9 | ||
| Con | 184 | 68 | (37.0) | ||||
| 11. Area of lesion considered to be fibrosis, % | 0–25 | PDT | 313 | 161 | (51.4) | 14.2 | 0.92 |
| Con | 153 | 57 | (37.3) | ||||
| 26–50 | PDT | 44 | 23 | (52.3) | 14.8 | ||
| Con | 24 | 9 | (37.5) | ||||
| >50 | PDT | 39 | 23 | (59.0) | 19.7 | ||
| Con | 28 | 11 | (39.3) | ||||
| 12. Lesion included blood | Yes | PDT | 133 | 72 | (54.1) | 18.9 | 0.48 |
| Con | 88 | 31 | (35.2) | ||||
| No | PDT | 266 | 139 | (52.3) | 12.8 | ||
| Con | 119 | 47 | (39.5) | ||||
*With last observation carried forward.
†Outcome as reported in the original journal article (the converse of the outcome also used in text of trial report of loss of 15 letters or more).
‡Test of interaction between subgroups.
§Definite hypertension was defined as systolic blood pressure of 160 mm Hg or higher or of 140–159 mm Hg with a history of hypertension or use of antihypertension medications, or diastolic blood pressure of 95 mm Hg or higher or of 90–94 mm Hg with a history of hypertension or use of antihypertension medications.
¶Approximate Snellen equivalent.